Organovo Holdings Inc.

About Organovo Holdings Inc.

Organovo, Inc. is a pioneering company focused on developing 3D human tissues for drug discovery, aiming to revolutionize the process of medical research and therapeutic development.

Products & Services

3D Bioprinting Technology:Innovative technology for creating 3D human tissues used in drug discovery and medical research.

Specialties

3D Bioprinting Drug Discovery Human Tissue Engineering

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise and At-the-Market Sales T: - FT: Warrant Exercise and At-the-Market Sales	A: 2300000 MR: - FA: approximately $2.3 million FAN: 2300000	D: 2025-03-06 FD: 2025-03-06	-
2	RT: Public Offering T: - FT: Public Offering	A: 5250000 MR: - FA: $5.25 Million FAN: 5250000	D: 2024-05-08 FD: 2024-05-08	-

Warrant Exercise and At-the-Market Sales Latest

2025-03-06

$2.3M

Public Offering 2024-05-08

$5.2M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Keith Murphy

Executive Chairman

A

Adam K. Stern

CEO of SternAegis Ventures and Head of Private Equity Banking at Aegis Capital Corp

A

Alison Tjosvold Milhous

Vice President, Accounting

D

David Gobel

Chief Executive Officer of Methuselah Fund LLC

D

Douglas Jay Cohen

President and Chief Executive Officer

N

Norman Staskey

Chief Financial Officer

View 4 more team members with Pro

Unlock Full Team Directory

Recent News